Breaking News:

Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
https://abivax.gcs-web.com/news-releases/news-release-details/abivax-completes-induction-treatment-last-patient-abx464-phase

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment B
  • Type of Listing: continuous
  • Number of shares: 14,394,243 as of January 31, 2021
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

LifeSci Capital Alpha Series:

Adam Evertts & David Sherman

Bryan, Garnier & Co:

Eric Le Berrigaud & Jean-Jacques Le Fur

goetzpartners securities:

Chris Redhead

Degroof Petercam:

Thomas Guillot

Kepler Cheuvreux:

Damien Choplain

Portzamparc:

Christophe Dombu

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254